Can the FDA-QRC Document be signed electronically?

Yes. Electronic signatures are legally binding in interstate commerce under the ESIGN Act (15 U.S.C. ch. 96, 2000) and in most states under UETA; ensure the method proves signer intent, attribution, and retention capability.

When is a digital (PKI) signature required?

Certain regulated records or internal policies may require PKI/digital signatures for non-repudiation and cryptographic integrity; consult 21 CFR Part 11 and internal quality policy to confirm requirements.

What if a signature needs notarization?

Notarization requirements depend on state law and document purpose. Use remote online notarization where permitted, and confirm identity-proofing and journal retention meet state notary rules.

How long must we retain signed FDA-QRC Documents?

Retention depends on content: financial tax records follow IRC §6501(a) minimums, HIPAA-covered items follow 45 CFR §164.530(j), and some records may require longer state-specific retention; keep the longest applicable period.

What authentication strength is recommended?

Use at least email-plus-code or enterprise SSO for routine records; stronger multi-factor or identity-proofing is advisable for high-risk filings or when required by 21 CFR Part 11.

How do we correct an already filed document?

Create a dated amendment or corrective report that references the original document ID, describe the correction, and obtain the same approvals and retention treatment as the original.

FDA-QRC Document

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

FDA-QRC Document

This Agreement is made and entered into as of the Effective Date below by and between:

Client Name:

Client Address

Consultant Name (FDA Quality Review Consultant):

Consultant Address

Effective Date:

Recitals

WHEREAS, Client is engaged in activities that require specialized regulatory quality review services relating to food, drug, and medical device regulatory submissions and compliance; and

WHEREAS, Consultant represents that it has the skill, experience and qualifications to provide quality review, gap analysis, and advisory services (collectively, Services) in accordance with applicable regulatory standards; and

WHEREAS, the parties desire to set forth the terms and conditions under which Consultant will perform the Services for Client.

Scope of Work

Consultant shall perform the Services described below and in any attached statement of work. Consultant will provide deliverables, timelines, staffing and acceptance criteria as set forth in the Scope of Work.

Describe Scope of Work

Payment Terms

As full compensation for the Services, Client shall pay Consultant in accordance with the following terms.

Total Fee Payment Schedule Invoice Frequency / Terms Late Payment Fee

Payments shall be made in U.S. Dollars unless otherwise agreed in writing. Client is responsible for any applicable taxes associated with payments under this Agreement, excluding taxes based on Consultant's net income.

Term and Termination

This Agreement shall commence on Start Date: and shall continue until End Date: , unless earlier terminated as provided herein.

Either party may terminate this Agreement for convenience upon written notice to the other party no fewer than days prior to the effective date of termination. Either party may terminate for material breach upon written notice if the breach is not cured within 15 days of receipt of notice of breach.

Post-Termination Obligations

Confidentiality

For purposes of this Agreement, "Confidential Information" means all non-public, proprietary or confidential information disclosed by one party to the other, whether oral, written or electronic, including regulatory strategies, submission materials, internal audits, non-public correspondence with regulators, technical data, and business information.

Receiving party shall: (a) use Confidential Information solely for performance of this Agreement; (b) restrict disclosure to those employees, contractors or advisors who need to know and who are bound by confidentiality obligations at least as protective as those herein; and (c) exercise at least reasonable care to protect Confidential Information from unauthorized disclosure. Confidential Information does not include information that: (i) is or becomes publicly available through no breach by receiving party; (ii) was known to receiving party prior to disclosure; (iii) is rightfully received from a third party without restriction; or (iv) is independently developed by receiving party.

If receiving party is compelled by law or legal process to disclose Confidential Information, receiving party shall provide prompt written notice to disclosing party (to the extent permitted) and cooperate reasonably in any effort to obtain confidential treatment or protective order. The obligations of confidentiality shall survive termination of this Agreement for years, except that trade secrets shall remain protected for so long as they qualify as trade secrets under applicable law.

Representations; Independent Contractor; Indemnity

Each party represents that it has the full right and authority to enter into this Agreement. Consultant is an independent contractor and not an employee, agent, or legal representative of Client for any purpose. Consultant shall be solely responsible for payment of Consultant's employees, contractors, taxes and benefits.

Each party shall indemnify and hold harmless the other party from and against any losses, damages or liabilities arising out of the indemnifying party's gross negligence or willful misconduct in performing its obligations under this Agreement, subject to any limitations of liability set forth below.

Limitation of Liability

Except for liability arising from a party's gross negligence, willful misconduct, breach of confidentiality, or indemnification obligations, neither party shall be liable to the other for incidental, consequential, special or punitive damages. Aggregate liability of either party for direct damages arising from this Agreement shall not exceed the total fees paid by Client to Consultant in the 12 months preceding the claim.

Governing Law; Venue

This Agreement shall be governed by and construed in accordance with the laws of the State of , without regard to conflict of laws principles. Exclusive venue for any dispute shall be the state or federal courts located in that State.

Entire Agreement; Amendments

This Agreement, including any statement of work or exhibits executed by the parties, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings. No amendment or waiver shall be effective unless in writing and signed by duly authorized representatives of both parties.

Miscellaneous

Neither party may assign this Agreement without the other party's prior written consent, except that either party may assign this Agreement in connection with a sale of substantially all of its assets or a change of control. Headings are for convenience only and do not affect interpretation. If any provision is held invalid, the remaining provisions shall remain in effect.

Additional Provisions / Notes

Client

Printed Name:

By:

Date:

Title:

Consultant (FDA QRC)

Printed Name:

By:

Date:

Title:

What the FDA-QRC Document Is and when it’s used

The FDA-QRC Document is a structured U.S.-centric regulatory record used to capture quality, compliance, or corrective-action information related to products, facilities, or processes that may be relevant to Food and Drug Administration oversight. It records findings, root-cause analysis, corrective and preventive actions (CAPA), attached evidence, and designated signatories. Organizations use the FDA-QRC Document to ensure consistent internal review, to assemble materials for submission to regulatory reviewers when required, and to maintain an auditable trail for inspections, audits, and enforcement reviews.

Why maintaining accurate FDA-QRC Documents matters

A well‑prepared FDA-QRC Document reduces regulatory risk, makes internal reviews faster, and establishes a clear audit trail for inspections. Accurate records support timely corrective actions and help demonstrate compliance with FDA expectations and industry best practices.

Typical teams and roles that complete FDA-QRC Documents

The FDA-QRC Document is commonly completed by cross-functional teams led by regulatory, quality, and product owners.

Regulatory Affairs: Prepares narrative responses and coordinates submissions to FDA or internal regulatory reviewers.
Quality Assurance: Documents findings, root cause, CAPA steps, and verification evidence for compliance records.
Engineering / Manufacturing: Provides technical details, test results, and implementation timelines for corrective actions.

Use this distribution to assign responsibility and ensure appropriate approvals before filing or submission.

Who signs and who approves

Regulatory Affairs Manager

Typically verifies regulatory applicability, confirms whether the issue meets reporting thresholds, and prepares or approves any submission package assembled for FDA review; often maintains the document as part of regulatory correspondence records.

Quality Assurance Director

Usually owns the corrective-action plan, signs off on root-cause findings and verification steps, and certifies that evidence and CAPA closure meet organizational quality policy and audit-readiness standards.

Essential sections every professional FDA-QRC Document should include

A clear, consistently organized record speeds review and reduces questions from auditors. The core sections below help reviewers find evidence, verify actions, and confirm closure.

Document Header

Unique ID, date, product/lot identifiers, location, and document owner to ensure traceability across systems and audits.

Executive Summary

Concise description of the issue, scope, and immediate impact so reviewers can assess severity without reading the full file.

Findings

Objective observations, test results, photographs, and referenced lab reports that substantiate the condition or event.

Root Cause Analysis

Methodology used, evidence examined, and concluded root cause to support proposed corrective actions and prevent recurrence.

Corrective Action Plan

Specific tasks, responsible owners, deadlines, and verification steps that define how the organization will remediate the issue.

Attachments and Evidence

Referenced supporting files such as lab reports, batch records, training logs, and validation documents needed for audit and review.

Step-by-step: complete and route an FDA-QRC Document

Follow these sequential steps to prepare, approve, and file the FDA-QRC Document while preserving a clear audit trail and meeting internal timelines.

01

Assemble evidence: Collect test reports, photos, lot records, and related attachments before drafting.
02

Draft findings: Record facts objectively, reference evidence, and avoid speculative statements.
03

Assign CAPA: Define actions, owners, and target dates in the corrective action section.
04

Approve and file: Obtain required signatures, then save final PDF with an audit trail for retention.

Where the FDA-QRC Document goes after approval

After final approvals, route the FDA-QRC Document to the appropriate internal and external destinations depending on regulatory obligations and internal retention policy.

Quality Management System: Primary repository for audit records and CAPA tracking.
Regulatory Affairs: Houses materials for potential FDA submissions or responses.
Executive Leadership: Receives summaries for high‑severity events or enterprise risk reporting.
External Filing: Submit to FDA only when reporting thresholds or inspection requests require it.

Typical digital workflow settings for online completion

Configure your eSubmission workflow to mirror internal approvals, authentication strength, and document retention policies.

Field	Configuration
Signature Type	Electronic signature (ESIGN/UETA) or PKI-based digital signature
Signer Authentication	Email link, SMS code, or multi-factor authentication
Attachments Required	Enable mandatory attachments for evidence files
Retention Policy	Set automated retention per records schedule

Technical considerations for electronic completion and sharing

Choose a platform that supports secure file types, strong authentication, and an auditable signing trail.

File formats: PDF, DOCX, and native form exports
Integrations: CRM/ERP and document storage connectors
Authentication: Email, SMS, or enterprise SSO

Ensure the platform can export tamper-evident signed PDFs, preserve attached evidence, and integrate with your records repository for retention.

Common eSignature vendor comparison for FDA-QRC Document workflows

Compare baseline pricing and common capabilities for eSignature platforms used to manage submission-ready records; signNow is listed first per vendor ordering rules.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by vendor	Varies by vendor	Varies by vendor	Varies by vendor
Bulk Send	Yes (Business Premium)	Varies by plan	Varies by plan	Varies by plan	Varies by plan
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Check vendor plans	Check vendor plans	Check vendor plans	Check vendor plans
Envelope Cap	No envelope cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Security and compliance features to include with electronic records

Encryption: TLS 1.2/1.3; AES-256 at rest

Audit Trail: Timestamped signature and event logging

Access Controls: Role-based permissions

Regulatory Certs: SOC 2 Type II; ISO 27001

FDA 21 CFR Part 11: Support 21 CFR Part 11 requirements

HIPAA: BAA available where required

Consequences of incomplete or inaccurate FDA-QRC Documents

Regulatory Action: Warning letters or consent decrees

Inspection Delays: Lengthier FDA follow-up

Product Holds: Manufacturing or distribution stoppage

Civil Penalties: Fines or monetary penalties

Reputational Harm: Market trust erosion

Legal Exposure: Increased litigation risk

Common preparation errors to avoid

Incomplete evidence: omitting lab reports, photos, or batch documentation that reviewers expect and will request.
Vague corrective actions: listing nonspecific remedies without owners or measurable completion criteria delays verification and closure.
Inconsistent identifiers: using different lot numbers or product codes across attachments breaks traceability and prompts audit queries.
Unauthorized signatures: failing to obtain authorized signatories or proper delegation records can invalidate approvals and require re-execution.

Typical internal timelines and processing expectations

Set internal deadlines that allow timely review and escalation; these targets help teams meet both internal SLAs and any external reporting obligations.

Initial Triage:

Document discovery and triage within 24–72 hours

Investigation Period:

Complete root-cause analysis within 30 calendar days

CAPA Assignment:

Assign actions within 7 business days after analysis

Verification:

Verify completion and effectiveness within agreed timeline

Reporting:

Escalate to regulatory affairs as required by internal rules

Frequently asked questions about electronic FDA-QRC Documents

Answers to common questions about legal validity, eSignature use, record retention, and practical filing scenarios for FDA-QRC Documents.

Need help? Contact support

Can the FDA-QRC Document be signed electronically?
Yes. Electronic signatures are legally binding in interstate commerce under the ESIGN Act (15 U.S.C. ch. 96, 2000) and in most states under UETA; ensure the method proves signer intent, attribution, and retention capability.
When is a digital (PKI) signature required?
Certain regulated records or internal policies may require PKI/digital signatures for non-repudiation and cryptographic integrity; consult 21 CFR Part 11 and internal quality policy to confirm requirements.
What if a signature needs notarization?
Notarization requirements depend on state law and document purpose. Use remote online notarization where permitted, and confirm identity-proofing and journal retention meet state notary rules.
How long must we retain signed FDA-QRC Documents?
Retention depends on content: financial tax records follow IRC §6501(a) minimums, HIPAA-covered items follow 45 CFR §164.530(j), and some records may require longer state-specific retention; keep the longest applicable period.
What authentication strength is recommended?
Use at least email-plus-code or enterprise SSO for routine records; stronger multi-factor or identity-proofing is advisable for high-risk filings or when required by 21 CFR Part 11.
How do we correct an already filed document?
Create a dated amendment or corrective report that references the original document ID, describe the correction, and obtain the same approvals and retention treatment as the original.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now